Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB1 | P15086 | 1/20 | 0.45 |
| ▸ | KIF11 | P52732 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | BHMT | Q93088 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4164445 | 0.85 | ALDH1A1 (0.43) | CPB1KIF11ALDH1A1CYP2C19POLB | |
| SCHEMBL20362609 | 0.82 | CPB1 (0.49) | CPB1KIF11ALDH1A1CYP2C19POLB | |
| SCHEMBL1478672 | 0.82 | CPB1 (0.49) | CPB1KIF11ALDH1A1CYP2C19POLB | |
| SCHEMBL20362608 | 0.82 | CPB1 (0.49) | CPB1KIF11ALDH1A1CYP2C19POLB | |
| SCHEMBL4154758 | 0.82 | CPB1 (0.49) | CPB1KIF11ALDH1A1CYP2C19POLB | |
| SCHEMBL16493607 | 0.77 | NOD1 (0.43) | BHMTSLC1A1 | |
| SCHEMBL22399771 | 0.76 | CPB1 (0.39) | CPB1ALDH1A1CYP2C19POLBCYP2C9 | |
| SCHEMBL416894 | 0.76 | KMT2A (0.37) | KIF11SMN1; SMN2KMT2ABHMTSLC1A1 | |
| SCHEMBL996039 | 0.76 | KMT2A (0.37) | KIF11SMN1; SMN2KMT2ABHMTSLC1A1 | |
| SCHEMBL6259101 | 0.76 | KMT2A (0.37) | KIF11SMN1; SMN2KMT2ABHMTSLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1933642-B1 | SALT ENHANCING COMPOUNDS AND USE | HOFMANN THOMAS FRANK (DE) | 2011-12-21 | — | — | EP | disclosed |
| US-20090155440-A1 | Salt Enhancing Compounds and Use | GIVAUDAN SA (CH) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155440-A1 | Salt Enhancing Compounds and Use | TAS1R1, TAS2R41, TAS2R40 | CPB1 1244/4885KIF11 2751/4885ALDH1A1 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.